AstraZeneca is planning to develop ISIS-ARRx broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy...Maxygen Inc., of Redwood City, Calif., said its board approved the liquidation and dissolution of the company, subject to shareholder approval, and plans to distribute all available cash to its shareholders after making reasonable provision for known and potential liabilities and other
Shire plc, of Dublin, settled litigation against Teva Pharmaceuticals USA Inc., a division of Teva Pharmaceutical Industries Ltd., of Jerusalem, related to Teva's abbreviated new drug application for a generic version of Shire's Intuniv (guanfacince) for attention deficit hyperactivity disorder...The settlement allows Teva a license to market its own generic versions of Intuniv or authorized versions of Intuniv provided by Shire
If approved, Lojuxta will be indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolemia (HoFH...according to the protocol, all patients were to have been treated with both bortezomib and lenalidomide prior to study entry
and cancellation of all outstanding employee stock options and other agreements granting rights to subscribe for purchase any shares or other securities in Allon...Oramed is required to pay royalties in the rate of 3 percent to 5 percent on sales of products and services derived from the technology developed using this and other OCS grants until the full amount is repaid, plus interest
As of the end of April, 943 employees, or about 77 percent, have had their future employment status clarified, including 300 employees who accepted the offer of transfers to other Merck Serono sites, 43 people who were redeployed through the creation of seven start-up companies and 80 employees that accepted early retirement...Merck Serono decided last year to shutter its Geneva headquarters. (See BioWorld Today, June 20, 2012
In other news, Perrigo received approval for the generic version of Sanctura XR (trospium chloride; Allergan Inc.) to treat overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency
IBC Generium is granted an exclusive license for other territories, and also has the right to an exclusive license for Russia and CIS states...The company plans to reconstruct an operational plant by overhauling the expansion facility that was under construction...Scynexis said it plans to progress the clinical development while evaluating new partnership opportunities
Additional funding of up to €9 million is anticipated in the following three years...In other news, Elan priced its offering of $850 million aggregate principal amount of 6.25 percent senior notes due 2021 by its wholly owned subsidiaries, Elan Finance public limited co
In separate news, Valeant said it received a received a complete response letter from the FDA for its new drug application for efinaconazole to treat onychomycosis...Questions raised by the FDA pertain to chemistry, manufacturing and controls related to areas of the container closure apparatus
Meanwhile, it will continue to seek partners to monetize its pipeline and technology platform assets...To that end, it will use the AMP-Rx protein design technology from Eleven Biotherapeutics Inc., of Cambridge, Mass., to create a therapeutic of its selection, optimized for improved pharmaceutical characteristics and therapeutic benefits
GlaxoSmithKline plc, of London, and the Biomedical Advanced Research and Development Authority (BARDA) agreed to a collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism...The public-private agreement calls for the Department of Health and Human Services to provide $40 million for the initial 18-month agreement and up to $200 million if the agreement is renewed over five years
The company's board previously recommended that shareholders vote to authorize the merger, and the parties expect to complete the deal as soon as practicable...Astellas also told AVEO it does not intend to fund any future trials in RCC under the firms' strategic collaboration inked in February 2011...Norgine holds marketing rights to Xifaxan in Australia, Belgium, Denmark, Egypt, Finland, France, Germany, Ireland, Luxembourg, the Netherlands, New Zealand, Norway, Switzerland, Sweden and the UK
It was developed to block the action of orexins, neurotransmitters in a specific part of the brain that help to keep a person awake...The company expects to begin trading on the NYSE on June 6 under its current stock symbol "PRGO," and will continue to trade on Nasdaq until the transfer takes place
Another revised proposal to approve an amendment to the 2011 Omnibus Incentive Plan, calls for a limit to the amount of the requested increase to 75 million shares of common stock (in the earlier proxy, an increase of 155 million shares was proposed
Under terms of the ASR, Merck agreed to an initial delivery of about 99.5 million shares based on current market prices...Pfizer Inc., of New York, said it intends to split off its remaining interest in Zoetis Inc., of Madison, N.J., the former animal health unit that recently completed its initial public offering...The completion of the full separation of Zoetis is expected to be accretive to Pfizer's earnings per share beginning in 2014
The batch was only distributed to and sold in Switzerland, and the recall is limited to the specific batch and to Switzerland...The companies will collaborate to advance the potential companion diagnostic, originally developed by Lilly
The Cell Therapy Catapult, which focuses on the development of the UK cell therapy industry, said it will work with London-based GlaxoSmithKline plc to explore potential collaborations in a range of areas relevant to the development of cell therapies, from research projects to technical and regulatory strategy
In addition to the stock investment, Aradigm may receive up to $25 million in development milestones, along with tiered royalties...Baxter said it will introduce HyQvia in select countries during 2013 and plans to expand the launch to other EU countries in 2014...Other data demonstrated that pharmacological inhibition of Usp14 by the company's small-molecule inhibitors stimulated degradation of the proteins in cell, neuron and brain slice models, suggesting the compounds' potential in a number of
The company plans to move ASM-024 into a Phase II trial in COPD later this year...His contributions to the field of oncology include more than 20 compounds brought into development, including the recently approved anticancer drugs Xalkori (crizotinib) and Inlyta (axitinib), discovered at Pfizer where O'Connor served as the global research therapeutic area head for oncology...Relmada is seeking to move LevoCap through approval using the 505(b)(2) pathway. (See BioWorld Today, Aug. 24, 2012
AstraZeneca is planning to develop ISIS-ARRx broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy...Maxygen Inc., of Redwood City, Calif., said its board approved the liquidation and dissolution of the company, subject to shareholder approval, and plans to distribute all available cash to its shareholders after making reasonable provision for known and potential liabilities and other